Floatz logo

Allogeneic Bone Marrow-Derived Mscs

Treatment-resistant Bipolar Depression

The University of Texas Health Science Center, HoustonCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Treatment-resistant Bipolar Depression cohort.

Asset / SponsorPhaseRating
Lurasidone
NeuroRx, Inc.
Phase 4A
LITHIUM, ELEMENTAL
Dr. Inge Winter
Phase 4BBB
Seroquel®
Dr. Inge Winter
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Joshua Rosenblat
Phase 4BBB
LAMOTRIGINE
Stony Brook University
Phase 4BBB

View all 50 →

Same molecule, other indications

Allogeneic Bone Marrow-Derived Mscs is also rated in:

lumbar disk degenerative disorderDormant
CCC
Indicative ·
54 / 100
View asset →
bone marrow failure syndromeDormant
CCC
Indicative ·
48 / 100
View asset →
Platinum-Resistant Fallopian Tube CarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →